The World Health Organisation (WHO) is planning to speak with the U.S. government and biotech firm Gilead …
"Gilead"
-
-
Industry & TradeTech/AI
Gilead says remdesivir coronavirus treatment will need a ‘sustainable model’ to keep it accessible
Gilead Sciences is doing its best to make experimental antiviral drug remdesivir accessible and affordable to coronavirus …
-
Industry & TradeTech/AI
Gilead to produce ‘several million’ rounds of remdesivir to help treat coronavirus patients in 2021
Gilead Sciences said on Thursday that it can produce “several million” rounds of its antiviral drug remdesivir in …
-
Industry & TradeTech/AI
U.S. FDA in ‘ongoing’ talks Gilead to make remdesivir available to coronavirus patients very soon
The U.S. Food and Drug Administration (FDA) said on Wednesday it has been in “sustained and ongoing” …
-
US Gilead Sciences it is aware of “positive data” from one of its studies looking at antiviral …
-
Japan announced on Tuesday that it would approve remdesivir, a antiviral drug made by U.S. firm Gilead …
-
Industry & TradeTech/AI
New data on Gilead’s remdesivir – released by accident – shows it flops in first coronavirus clinical trial
Remdesivir developed by Gilead Sciences, a potential antiviral drug to treat coronavirus, has failed in its first …
-
International NewsNewsunclassified
Gilead drug shows ‘rapid’ recovery in coronavirus cases, yet it is too early to celebrate
University of Chicago Medicine researchers said they saw “rapid recoveries” in 125 patients with coronavirus taking Gilead …
-
StocksUSA
U.S. stocks surge after Gilead’s promising coronavirus vaccine results, Dow ends highest since March
by Yomna Yasserby Yomna YasserU.S. stocks jumped on Friday after a report on a Gilead Sciences drug that showed some effectiveness in treating …
-
Industry & TradeTech/AI
Investors must be cautious with Gilead’s potential coronavirus drug Remdesivir, analysts say
by Yomna Yasserby Yomna YasserAs a new report by STAT News showed Gilead’s experimental drug Remdesivir as a promising update on …